Flow cytometry confirmed the substantial activation of both CD4+ and CD8+ T cells, while apoptosis assays showed selective tumor cytotoxicity (>55% tumor apoptosis) with minimal impact on non-malignant cells (>92% viability). This evidence concerns the gene CD8A and neoplasm.